SCHEMBL4640997

SCHEMBL4640997

COC(=O)Oc1ccc2c(c1)[nH]c(=O)n2CCC(C)(C)NC(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
RAB9A P51151 1/20 0.36
CALCRL Q16602 1/20 0.36
EPHX2 P34913 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
PPARG P37231 2/20 0.34
HPGD P15428 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HTR7 P34969 3/20 0.34
MDM2 Q00987 1/20 0.33
HTR1A P08908 1/20 0.33
CTSL P07711 1/20 0.33
MAOB P27338 1/20 0.33
AAK1 Q2M2I8 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4915938 0.84 ALDH1A1 (0.47) MEN1KMT2ARAB9AEPHX2PPARG
SCHEMBL4640487 0.83 KMT2A (0.41) MEN1KMT2ARAB9ACALCRLEPHX2
SCHEMBL4640794 0.73 MEN1 (0.38) MEN1KMT2ARAB9ACALCRLEPHX2
SCHEMBL4639963 0.70 ADRB3 (0.42)
SCHEMBL4398728 0.69 MEN1 (0.45) MEN1KMT2AEPHX2PPARGHTR1A
SCHEMBL891295 0.68 DYRK1A (0.49) CALCRLL3MBTL1
SCHEMBL13306513 0.68 PDPK1 (0.56)
SCHEMBL3390372 0.67 MEN1 (0.51) MEN1KMT2ARAB9ASMN1; SMN2HPGD
SCHEMBL13306474 0.67 CA12 (0.51) MAOB
SCHEMBL15183122 0.67 CNR2 (0.48) MEN1KMT2ARAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1943229-A1 BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-07-16 EP disclosed
WO-2007048842-A1 BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-03 WO disclosed